Experimental cocktail aims to neutralize deadly grain fumigant poisoning
NCT ID NCT07451561
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a combination of three drugs—glucose-insulin-potassium (GIK), hydrocortisone, and sevelamer—in 74 people with severe aluminum phosphide poisoning. The goal is to see if this mix can lower death rates by countering shock and directly neutralizing the toxic gas. Participants must be between 12 and 60 years old, in shock, and treated within 12 hours of ingestion.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Glucose-insulin-potassium (GIK) infusion, intravenous hydrocortisone, and oral sevelamer
- What this could lead to
- If it works, this could point toward an effective treatment for aluminum phosphide poisoning, which currently has no antidote.
- What could go wrong
- This is a small, early-stage trial with only 74 participants, so results may not apply widely. The combination therapy also carries risks like blood sugar and potassium imbalances.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 74 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmed history of ALP ingestion and clinical symptoms and signs of toxicity. * Age of Cases (12 - 60 years). * Shocked cases (Mean arterial blood (MAP) less than 70 mmHg). * Presentation within 12 hours of ingestion. Exclusion Criteria: * Co-ingestion of other toxins. * Chronic cardiac/renal/hepatic failure and diabetic patients. * Pregnancy. * Cases arriving in terminal cardiac arrest. * Cases refused to participate in the trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute aluminum phosphide poisoned cases are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sohag university hospital
Sohag, 82611, Egypt